Claims for Patent: 10,723,786

Summary for Patent: 10,723,786

Title:	RSV-specific binding molecule
Abstract:	The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
Inventor(s):	Beaumont; Tim (Ouderkerk aan de Amstel, NL), Bakker; Adrianus Q. (Hoorn, NL), Yasuda; Etsuko (Amsterdam, NL)
Assignee:	MedImmune, Limited (Cambridge, GB)
Application Number:	16/047,524
Patent Claims:	1. An antibody, or functional part thereof, wherein the antibody or functional part thereof specifically binds to a Respiratory Syncytial Virus (RSV) F protein, comprises a heavy chain CDR1 sequence comprising the sequence KLSIH (SEQ ID NO:4), a heavy chain CDR2 sequence comprising the sequence GYEGEVDEIFYAQKFQH (SEQ ID NO:8), a heavy chain CDR3 sequence comprising the sequence LGVTVTEAGLGIDDY (SEQ ID NO:12), a light chain CDR1 sequence comprising the sequence RASQIVSRNHLA (SEQ ID NO:20), a light chain CDR2 sequence comprising the sequence GASSRAT (SEQ ID NO:24), and a light chain CDR3 sequence comprising the sequence LSSDSSI (SEQ ID NO:28), and wherein the antibody, or functional part thereof, comprises a Fc region comprising a modification at one or more positions selected from the group consisting of 234, 235, 236, 237, 238, 239, 240, 241, 243, 244, 245, 247, 251, 252, 254, 255, 256, 262, 263, 264, 265, 266, 267, 268, 269, 279, 280, 284, 292, 296, 297, 298, 299, 305, 313, 316, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 339, 341, 343, 370, 373, 378, 392, 416, 419, 421, 440 and 443 as numbered by the EU index of Kabat, said modification comprising an amino acid substitution, and/or an amino acid insertion, and/or an amino acid deletion. 2. The antibody or functional part thereof of claim 1, wherein the antibody or functional part thereof comprises a human IgG1 heavy chain. 3. The antibody or functional part thereof of claim 2, wherein the Fc region modification comprises amino acid substitutions at amino acid positions 252, 254, and/or 256. 4. The antibody or functional part thereof of claim 3, wherein the amino acid substitution at amino acid position 252 is a substitution with tyrosine, the amino acid substitution at amino acid position 254 is a substitution with threonine, and/or the amino acid substitution at amino acid position 256 is a substitution with glutamic acid. 5. The antibody or functional part thereof of claim 3, wherein the amino acid substitution at amino acid position 252 is a substitution with tyrosine, the amino acid substitution at amino acid position 254 is a substitution with threonine, and the amino acid substitution at amino acid position 256 is a substitution with glutamic acid. 6. A pharmaceutical composition comprising the antibody or functional part thereof of claim 1. 7. A pharmaceutical composition comprising the antibody or functional part thereof of claim 3. 8. A pharmaceutical composition comprising the antibody or functional part thereof of claim 5. 9. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the antibody or functional part thereof of claim 3. 10. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the antibody or functional part thereof of claim 5. 11. A pharmaceutical composition comprising an isolated antibody or functional part thereof of claim 1 and at least one other isolated RSV-specific antibody or functional part thereof. 12. The pharmaceutical composition of claim 11 wherein the at least one other isolated RSV-specific antibody or functional part thereof specifically binds to the RSV F protein and comprises: a heavy chain comprising the CDR1, CDR2, and CDR3 sequences of palivizumab and a light chain comprising the CDR1, CDR2, and CDR3 sequences of palivizumab; or a heavy chain comprising the CDR1, CDR2, and CDR3 sequences of D25 and a light chain comprising the CDR1, CDR2, and CDR3 sequences of D25; or a heavy chain comprising the CDR1, CDR2, and CDR3 sequences of AM14 and a light chain comprising the CDR1, CDR2, and CDR3 sequences of AM14; or a heavy chain comprising the CDR1, CDR2, and CDR3 sequences of AM16 and a light chain comprising the CDR1, CDR2, and CDR3 sequences of AM16; or a heavy chain comprising the CDR1, CDR2, and CDR3 sequences of AM23 and a light chain comprising the CDR1, CDR2, and CDR3 sequences of AM23. 13. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the antibody or functional part thereof of claim 2. 14. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the antibody or functional part thereof of claim 4. 15. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 6. 16. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 7. 17. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 8. 18. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 11. 19. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 12.

Details for Patent 10,723,786

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2029-10-06
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2029-10-06